CME|Articles|November 20, 2026

Psychiatric Times

  • Vol 43, Issue 11

Long-Acting Injectable Antipsychotics: Balancing Evidence, Ethics, and Patient Care

Listen
0:00 / 0:00

Key Takeaways

  • Patients value relapse prevention and functional stability with LAIs, yet may fear injection pain, adverse effects persistence, and coercion; cost remains a cross-stakeholder barrier requiring proactive navigation.
  • Caregivers often learn about LAIs only when clinicians introduce them, underscoring the need for structured education on benefits, adverse effects, and caregiver roles in adherence and coordination.
SHOW MORE

In this CME article, explore the clinical evidence and ethical reasoning to guide use of long-acting injectable antipsychotics in patient care.

CATEGORY 1 CME

Premiere Date: November 20, 2026

Expiration Date: May 20, 2028

ACTIVITY GOAL

The goal of this activity is to provide clinicians with clinical evidence and ethical reasoning to guide their use of long-acting injectable antipsychotics (LAIs) in patient care.

LEARNING OBJECTIVES

1. Appreciate patient, caregiver, and clinician perspectives on the use of LAIs.

2. Apply clinical-ethics recommendations for the use of LAIs in their practice.

TARGET AUDIENCE

This accredited continuing education (CE) activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.

ACCREDITATION/CREDIT DESIGNATION/FINANCIAL SUPPORT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC, and Psychiatric Times. Physicians’ Education Resource, LLC, is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is funded entirely by Physicians’ Education Resource, LLC. No commercial support was received.

OFF-LABEL DISCLOSURE/DISCLAIMER

This accredited CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited CE activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource, LLC.

FACULTY, STAFF, AND PLANNERS’ DISCLOSURES AND CONFLICT OF INTEREST MITIGATION

None of the staff of Physicians’ Education Resource, LLC or Psychiatric Times or the planners or the authors of this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing health care products used by or on patients.

For content-related questions, email us at PTEditor@mmhgroup.com; for questions concerning the accreditation of this CME activity or how to claim credit, please contact info@gotoper.com and include “Long-Acting Injectable Antipsychotics: Balancing Evidence, Ethics, and Patient Care” in the subject line.

HOW TO CLAIM CREDIT

PER® is an ACCME Innovation Partner. As an ACCME Innovation Partner, PER® offers physician learners the option, upon completion of the activity evaluation, to request that their CME credit be reported on their behalf to the ACCME and made available in CME Passport™, ACCME's free, centralized CME data system. CME Passport™ is a free, centralized service from the ACCME that enables physicians to find, track, and share CME credit reported on their behalf by accredited providers. Learn more at www.cmepassport.org.

Once you have read the article, please use the following URL to evaluate and request credit: https://education.gotoper.com/activity/ptcme26nov. If you do not already have an account with PER®, you will be prompted to create one. You must have an account to evaluate and request credit for this activity.


Part 1 of this CME activity examined the application of ethical principles to emerging clinical dilemmas regarding the use of long-acting injectable antipsychotics (LAIs) for psychotic disorders. Despite increasing evidence that LAIs have an overall beneficial profile, there have been continued barriers in the knowledge and attitudes of clinicians, patients, and caregivers that have prevented optimal use of LAIs.1

This article will primarily draw from large multinational studies, meta-analyses, and systematic reviews prioritizing data from the United States when available to minimize cultural differences.2-4 Analysis of these studies will confirm the ethical concerns raised in part 1, and call for revision of received assumptions or emphasize the need for more research before an ethical recommendation can be made. Based on these empirical findings, we will present best practices for education, shared decision-making, and informed consent processes.

Patient Perspectives on LAIs

For patients, the pharmaco-ethical benefits of LAIs are primarily the convenience of the long-acting formulation, greater efficacy, and their ability to provide a more stable course of illness with fewer symptom fluctuations than with oral agents (OAs), as well as likely improved long-term functioning. In the ADVANCE study, patients believed OAs had more short-term adverse effects than LAIs. Some clinician views were affirmed: They expressed apprehension about the pain injections cause patients and the possible coercive impact of LAIs on therapeutic relationships. Clinicians and patients alike worry about the cost of the medications.2 Table 1 examines patient perspectives on LAIs vs OAs.2

Caregiver Perspectives

Caregiver perspectives on LAIs have been relatively neglected until recently, when researchers recognized that caregivers perform critical functions in LAI use. Caregivers—whether family, friends, or professionals—monitor and encourage adherence, provide psychosocial assistance, and facilitate practical coordination of the patient’s treatment plan. They also support a patient’s decisions or serve as surrogate decision makers for incapacitated patients.

The ADVANCE study conducted qualitative interviews with patients, caregivers, and clinicians about their experiences and perceptions of LAIs in 8 countries, including the United States. Approximately 89% of caregivers of patients with schizophrenia reported they had not heard about LAIs until their clinician introduced the option. Caregivers endorsed the need for more education on LAIs, particularly information about adverse effects.2 Table 2 lists advantages and disadvantages of LAIs compared with OAs from the caregiver viewpoint.

Clinician Perspectives

One of the most significant studies connecting the attitudes of American clinicians toward LAIs and their clinical practices using them is the US Decide survey. The 380 clinician respondents were divided into 4 groups according to their beliefs about the use of LAIs in patients with schizophrenia: early users, severity reserved, adherence reserved, or LAI hesitant. Participants were also characterized as either low or high users of LAIs. High LAI users (greater than 31% of patients on LAIs) endorsed a higher degree of competence and confidence in LAI management, for example, negotiating with insurance companies to secure payment, compared with low users (fewer than 14% on LAIs). Clinicians in the high LAI use group or who endorsed an early use mindset about LAIs predicted a larger percentage of patients would accept LAIs than those in other subgroups. The authors’ conclusion underscores the complex obstacles that will need to be overcome to change clinician culture surrounding LAIs: “These results indicate that multiple factors (eg, environmental/demographic factors, access, attitudes, motivation, knowledge/confidence) combine to influence LAI use and highlight the need to tailor educational materials aimed at improving patient outcomes through increased LAI use.”3

Case Study Revisited

In part 1 of this CME, we met “Jake,” a man aged 19 years who was admitted to an inpatient psychiatric unit following his first psychotic break. During his hospital stay, Jake was diagnosed with schizophrenia and stabilized on oral aripiprazole. The attending psychiatrist, “Dr Y,” suggested switching Jake to an LAI to prevent relapse upon discharge, but fellow members of the treatment team objected, stating that Jake deserved a chance to show he could manage his own illness and did not want to undermine his trust in the treatment team. Dr Y then realized the team members had ethical objections to the use of LAIs for early-episode psychosis and took the opportunity to educate the staff about new shared decision-making approaches to LAIs that would address many of their ethical concerns.

As Dr Y requested, the trainees present their research on clinical and ethical issues related to LAIs at the psychiatry unit staff meeting. A lively discussion ensues. At the end of the meeting, the entire treatment team agrees, based on what they have learned, that Dr Y should have an informed consent discussion with Jake and—with his permission—his mother about the possibility of switching his current OA to an LAI upon discharge.

When Dr Y initially presents the option to Jake and his mother, his mother is visibly upset but lets her son speak first. Jake responds: “I don’t like needles much, but I do like the idea of a lower chance of having another episode. I don’t want to be admitted to the hospital again and miss more school. If this injection will help me finish my training, then I am all for it.” Jake’s mother then replies: “I cannot believe you would inject my son with antipsychotics when he has just been diagnosed with schizophrenia. I am a sociologist. Do you think I don’t know about the abuses in psychiatry? This is one more example of the profession’s paternalistic lack of respect for patient autonomy.”

Since Jake does not share her sentiments, his mother agrees to at least listen to Dr Y discuss the clinical evidence and ethical issues, as they impact the care of her son.

Shared Decision-Making

Expert consensus recommends a shared decision-making approach to overcome barriers to LAI use (Table 3).4-6 Where implemented, it has had positive outcomes, yet there are prudential, time-management, and entrenched practitioner attitudes that LAIs should be reserved for patients with severe illness and/or nonadherence that have limited its utility.7 The empirical ethics reviewed above and in part 1 identify several key considerations that should inform this approach.

First, the data presented show that there is substantial overlap in patient, caregiver, and clinician views that contribute to the limited use of LAIs. There are also areas where beliefs diverge that warrant deliberate, empathic attention from the clinician discussing LAIs with patients and caregivers.

Second, a systematic review of patient experiences with LAIs identified 3 broad categories that can serve as either positive or negative drivers of patient and caregiver decisions about LAIs.4 The categories are the pharmacology of the LAI and OA antipsychotic; the contextual features surrounding the delivery of the LAI; and the strength, flexibility, and mutual trust of the therapeutic relationship.4 An LAI treatment team, rather than a single clinician, whenever possible, should compassionately and comprehensively address these domains. Each category is applied to Jake’s case in the following section.

Third, discussions should begin and end with the patient’s goals, based on their own values/preferences, and consider how LAIs might impede or promote them.8 In Jake’s case, his priority was being able to reduce relapses, have the stability to finish his training program, and be able to work in his chosen field, even if he did not like injections. The psychiatrist then brings their pharmacoethical knowledge of LAIs to the decision-making. For example, Dr Y should share with Jake and his mother the evidence that patients on LAIs may have a more stable course of disease. With LAIs, Jake may experience decreased relapses and hospitalizations, a lower likelihood of detrimental impacts such as structural brain changes, and improved long-term function. The psychiatrist is also obligated to provide a balanced picture: If Jake experiences adverse effects, it will take longer for them to dissipate, and patients do experience relapses, even on LAIs.5

Based on Jake’s priorities, Dr Y recommends an extended-interval agent that requires fewer appointments. Dr Y ensured the efficacy and tolerability of the OA before transitioning to its long-acting form. In the shared decision-making process, the psychiatrist had an ethical obligation to be aware of and account for his own biases and blind spots. In Jake’s case, this could be a belief that LAIs should not be used in first-episode or early schizophrenia. If Dr Y, based solely on his own attitudes, had declined to offer Jake an LAI, this would not be ethically justifiable given what is known about the benefits of LAIs in achieving Jake’s treatment goals. This would be even more ethically problematic if Jake requested an LAI, as this reinforces the psychiatrist’s authority instead of enhancing Jake’s autonomy. Patients should also be informed of alternative behavioral interventions that may boost adherence, and their declination of LAIs should be respected with judicious reintroduction at future visits.

Informed Consent

Ethicists distinguish 3 main components of informed consent, illustrated in the Figure: information relevant to the index treatment or procedure must be communicated in a form that is comprehensible to the specific patient; the patient must possess adequate decisional capacity to accept or reject the treatment offered; the patient must have sufficient voluntarism to make a free and authentic choice.9 Each of these components needs to be optimized in the informed consent process for LAIs.

Although estimates vary, there is general agreement that LAIs are underused in the US. The most prevalent and persistent obstacle may be clinician ambivalence and lack of familiarity, which influence their confidence and competence in communicating with patients about LAI options.10 The American Psychiatric Association Code of Ethics With Annotations for Psychiatry codifies clinicians’ professional obligation to pursue continuing education about emerging treatments.11 Without this education about LAIs, clinicians cannot serve as authoritative sources of information for patients about all available treatment options, especially early in the course of the illness. Clinicians may not even think about an LAI for nonadherent patients with bipolar disorder or schizoaffective disorder, although they have demonstrated similar efficacy and acceptance.12

Clinicians who are hesitant to prescribe LAIs may ethically believe the risks outweigh the benefits. They may be less reluctant if they learn that more harm probably comes from repeated failed treatment attempts with OAs, including involuntary interventions due to pseudoresistance (presuming the patient is adherent to OAs) that may be reduced with an LAI.10 There are encouraging findings that clinician knowledge, skills, attitudes, and motivations related to the use of LAIs all respond positively to targeted education.3

Decision-Making Capacity

There is relatively little literature explicitly assessing patient capacity to provide informed consent for LAIs. One study on consent for LAIs investigated withdrawal of that consent. A meta-analysis of randomized controlled trials found that patients are no more likely to withdraw their consent for treatment with LAIs than for OAs, indicating that patients may be more willing to continue LAIs than clinicians expect.13

A retrospective study of 65 patients in an LAI clinic in Greece found impairments in the informational component of capacity, whereas over 70% of the participants demonstrated adequate appreciation; the authors recommended full capacity assessments to identify patients with clinical indications of diminished capacity.14 Even patients who, like Jake, may technically have capacity often want friends or family to be involved in decision-making. Given the importance of caregivers in helping patients manage their illness, more research is needed on the role of surrogates in providing informed consent for LAIs and their place in psychiatric advance directives.

Coercion and Voluntarism

An article from 2004 proposed that not all patients may perceive LAIs as diminishing voluntarism and that the clinician assumption that patients see LAIs as inherently more coercive than OAs may not be valid in all cases.15 Evidence now provides qualified support for these proposals. Patients who first experienced LAIs in inpatient settings, particularly if they were committed or the treatment was over their objection, view LAIs as more coercive. This may explain data from older studies that found patients had higher rates of seeing LAIs as coercive. Patients who are introduced to LAIs in an outpatient environment are far less likely to consider LAIs as restricting their voluntarism.16

Financial Incentives

As discussed in part 1, the potential coercive impact of offering financial incentives to patients has been controversial. Concerns have been raised that incentives may impede the patient’s ability to make a voluntary decision about LAIs and undermine the patient’s trust in the fiduciary nature of the therapeutic alliance.17 Empirical work shows a more nuanced picture of the ethical issues. The Money for Medication (M4M) randomized controlled trial found that 88% of patients and 81% of clinicians considered financial incentives to be ethically acceptable. An unexpected finding was that some clinicians felt the incentives strengthened the treatment relationship.18 However, the Veterans Affairs/Department of Defense guideline on the treatment of schizophrenia found the extant evidence insufficient to recommend for or against the use of financial incentives.19 Thus, any use of financial incentives for LAIs must be attuned to the ethical aspects of the intervention and prioritize patient self-determination.

Case Conclusion

After hearing Dr Y’s discussion of the most recent research showing that early initiation of an LAI may offer her son the best chance to complete his vocational program and live independently, which has only increased Jake’s desire to switch to an LAI, Jake’s mother agrees. Jake receives his first LAI dose before discharge and follows up with the LAI clinic.

Concluding Thoughts

There are numerous systemic obstacles and health delivery impediments that unfairly limit access to LAIs for persons with psychotic disorders. The treatment team caring for Jake would also have an ethical duty to advocate to the insurance company or other payer source to try to obtain funds for the LAI. They could make the evidence-based argument that the LAIs may reduce the long-term costs of repeated hospitalizations.20 Jake is fortunate because the health care system in which he was treated had an LAI clinic where he could form a relationship with a dedicated team of mental health professionals, who had the infrastructure and training to store and administer LAIs.1

Research shows these factors are critical for positive outcomes with LAIs. The government needs to make these specialized clinics more widely available, especially to rural and minoritized patients. Trauma-informed and harm-reduction approaches should be available to patients who have had prior negative experiences with LAIs.21 Organized psychiatry must advocate for expansion of access to second-generation agents and encourage research that demonstrates LAIs not only reduce the negative aspects of psychotic disorders but also have a positive impact on the overall well-being of patients, especially early in the course of their psychotic illness.19

Dr Geppert is professor emeritus of psychiatry and internal medicine and director of ethics education at the University of New Mexico School of Medicine in Albuquerque. She is an adjunct professor of bioethics at the Alden March Bioethics Institute of Albany Medical College and lecturer in bioethics at Columbia University School of Professional Studies in New York, New York. She serves as the ethics editor for Psychiatric Times.

References

1.Lindenmayer JP, Glick ID, Talreja H, Underriner M. Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia. J Clin Psychopharmacol. 2020;40(4):346-349.

2.Franzenburg KR, Hansen R, Suett M, et al. Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE study. Front Psychiatry. 2025;16:1645328.

3.Velligan D, Salinas GD, Belcher E, et al. Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey. BMC Psychiatry. 2025;25(1):232.

4.Aprile SF, Rodolico A, Di Francesco A, et al. Oral versus long-acting injectable antipsychotics in schizophrenia spectrum disorders: a systematic review of patients’ subjective experiences. Psychiatry Res. 2025;348:116460.

5.Fagiolini A, Cuomo A, De Berardis D, et al. Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review. Int Clin Psychopharmacol. 2025;40(6):e1-e13.

6.Kane JM, McEvoy JP, Correll CU, Llorca PM. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs. 2021;35(11):1189-1205.

7.Fitzgerald I, Sahm LJ, Maidment I, et al. From idealist to realist-designing and implementing shared decision-making interventions in the choice of antipsychotic prescription in people living with psychosis (SHAPE): a realist review. Schizophr Bull. 2025;51(4):916-932.

8.Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5):IN18031AH1C.

9.Roberts L, Hoop J, Dunn LB, Geppert CMA. An overview for mental health clinicians, researchers, and learners. In: Roberts LW, Hoop JG, eds. Professionalism and Ethics Q & A Self-Study Guide for Mental Health Professionals. American Psychiatric Publishing; 2008.

10.Haddad PM, Correll CU. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opin Pharmacother. 2023;24(4):473-493.

11.The Principles of Medical Ethics With Annotations Especially Applicable to Psychiatry. American Psychiatric Association; 2013.

12.McIntyre RS, Yildirim M, Loomer S, et al. Understanding patient, caregiver, and prescriber preferences for an antipsychotic regimen administered once every 2 months for schizophrenia or bipolar I disorder: a qualitative interview study in North America. Curr Med Res Opin. 2025;41(10):1965-1980.

13.Yaegashi H, Misawa F, Noda H, et al. Risk of withdrawal of consent for treatment with long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled trials. Schizophr Res. 2021;229:94-101.

14.Nystazaki M, Pikouli K, Tsapakis EM, et al. Decision-making capacity for treatment of psychotic patients on long acting injectable antipsychotic treatment. Arch Psychiatr Nurs. 2018;32(2):300-304.

15.Roberts LW, Geppert CM. Ethical use of long-acting medications in the treatment of severe and persistent mental illnesses. Compr Psychiatry. 2004;45(3):161-167.

16.Patel MX, de Zoysa N, Bernadt M, et al. Are depot antipsychotics more coercive than tablets? The patient’s perspective. J Psychopharmacol. 2010;24(10):1483-1489.

17.Claassen D. Financial incentives for antipsychotic depot medication: ethical issues. J Med Ethics. 2007;33(4):189-193.

18.Noordraven EL, Schermer MHN, Blanken P, et al. Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients’ and clinicians’ perspectives after a 12-month randomized controlled trial. BMC Psychiatry. 2017;17(1):313.

19.VA/DOD Clinical Practice Guideline. US Government Printing Office; 2023.

20.Awasthi S, Huang D, Bell Lynum KS, Nag SS. The effect of early initiation of aripiprazole once-monthly 400 mg on health care resource utilization and health care costs in patients diagnosed with bipolar I disorder: real-world evidence from US claims data. J Manag Care Spec Pharm. 2026;32(1):66-74.

21.Aldridge MA. Addressing non-adherence to antipsychotic medication: a harm-reduction approach. J Psychiatr Ment Health Nurs. 2012;19(1):85-96.




Related to this article